Forging ahead with its new three-year business plan, Chugai Pharmaceutical enjoyed rosy earnings in the first half of 2019, bolstered by the outperformance of the Hemlibra (emicizumab) hemophilia drug and its I/O star Tecentriq (atezolizumab). But with a biosimilar onslaught…
HOME > ACADEMIA
ACADEMIA
- Nobel Laureate Honjo Says Rewards for Opdivo Patent Too Small
April 12, 2019
- Xofluza Shouldn’t Be Used Alone for Hong Kong Flu: Specialist
April 8, 2019
- With Continuing Shortage of Cefazolin, Shipments of 21 Substitutes Being Adjusted Too
April 8, 2019
- Discuss Biosimilar Pricing Separate from High-Cost Medical Expense Benefits: Prof.
March 20, 2019
- NCNP to Set Up New Council to Accelerate Clinical Development of Neuromuscular Disorder Treatments
March 18, 2019
- Feburic Prevents Cerebral, Cardiorenovascular Events: Japan Multicenter Study
March 13, 2019
- Investigators Calling Off Trials on First Hyperlactacidemia Drug with No Significant Improvement Shown
February 28, 2019
- Keio Researchers Start Studying ReQuip for ALS after iPS Screening
February 25, 2019
- Japan OKs World’s 1st iPS Cell Clinical Research for Spinal Cord Injuries
February 19, 2019
- Revised Hyperuricemia Treatment Guidelines Recommend Uric Acid Production Inhibitors to Prevent Kidney Function Decline
January 21, 2019
- Concomitant Insulin a Must for Suglat Use in Type 1 Diabetes: Specialist
January 18, 2019
- 8-Week Treatment with Maviret a Promising First-Line Option for Hepatitis C: Hepatologist
January 11, 2019
- Tokyo Medical and Dental Univ. to Launch Investigator-Led Trial for JAK Inhibitor for CAEBV
January 10, 2019
- Keio Univ. Board OKs World’s 1st iPS Cell Clinical Research for Spinal Cord Injuries
November 29, 2018
- Health Economist Calls for Robust Appraisal Process in Japan CEA System
November 20, 2018
- World’s 1st, Keio Univ. Plans iPS Cell Clinical Research for Spinal Cord Injuries
November 15, 2018
- Hematology Specialist Advises Caution in Using Hemlibra in Children
October 30, 2018
- Research Group Builds New Pathogenic Variants Database for Japanese Hereditary Breast Cancer
October 16, 2018
- I/O Pioneers Win Nobel Prize in Medicine; Honjo Prods Japan Firms to Make More Academic Investment at Home
October 2, 2018
- New Treatment GL for Statin Intolerance Compiled by Atherosclerosis Society, 3 Other Academic Societies
October 1, 2018
ページ
Generic drug makers are making greater efforts to disclose more information on their products after years of repeated requests from doctors and medical institutions, which want to better ascertain their quality and stability of their supplies.Ohara Pharmaceutical has been disclosing…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In 2011 the Japanese pharmaceutical industry was rocked when a whistleblower exposed the falsification of trial data for the drug Diovan, the blockbuster blood pressure drug manufactured by pharma giant Novartis. The ensuing investigation led to the arrest of one…